Skip to main content
. Author manuscript; available in PMC: 2017 Jul 1.
Published in final edited form as: Antiviral Res. 2016 Apr 12;131:40–48. doi: 10.1016/j.antiviral.2016.04.007

Figure 2. Treatment of dstet5 cells with multiple hepadnaviral DNA polymerase inhibitors resulted in the accumulation of the novel sub-genomic RNA species.

Figure 2

(A) dstet5 cells were treated with the indicated viral DNA polymerase inhibitors for 3 days. DHBV RNA and core-associated DNA were analyzed by Northern and Southern Blot hybridization assays, respectively. (B) Lamivudine induces the accumulation of the novel RNA species in a dose-dependent manner. dstet5 cells were treated with the indicated concentrations of lamivudine for 3 days in the absence of tet. DHBV RNA and core-associated DNA were analyzed as described above. Ribosomal RNAs (28S and 18S rRNA) served as loading controls. The positions of DHBV pgRNA and subgenomic mRNA encoding viral envelope proteins (envRNA) are indicated. The RNA species accumulated in the cells treated with DNA polymerase inhibitors are indicated as novel RNA. For core-associated DHBV DNA, the forms of relaxed circular (RC), double stranded linear (DSL) and single stranded (SS) DNA are indicated.